

Special Issue

Research on Development of Norovirus Vaccines

Message from the Guest Editor

Norovirus is the most predominant viral agent of acute gastroenteritis outbreaks, being responsible for at least 50% of all AGE outbreaks worldwide. Norovirus can infect people of all ages and is extremely infectious. NoVs are basically transmitted by the fecal-to-oral route, and use three general modes: person-to-person, foodborne, and water-borne. Norovirus is estimated to cost approximately 4.2 billion in health care costs and over \$60 billion in societal costs globally each year. However, there is no vaccine for norovirus at the moment. Hence, this Special Issue will focus on recent research related to the development of norovirus vaccines.

Guest Editor

Prof. Dr. Soonyoung Paik

Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea

Deadline for manuscript submissions

closed (30 April 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/40435

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).